



This is a repository copy of *Staphylococcus aureus* adaptation to aerobic low-redox-potential environments: implications for an intracellular lifestyle.

White Rose Research Online URL for this paper:
<https://eprints.whiterose.ac.uk/146733/>

Version: Accepted Version

Article:

Christmas, B.A.F., Rolfe, M.D., Rose, M. et al. (1 more author) (2019) *Staphylococcus aureus* adaptation to aerobic low-redox-potential environments: implications for an intracellular lifestyle. *Microbiology*, 165 (7). pp. 779-791. ISSN 1465-2080

<https://doi.org/10.1099/mic.0.000809>

© 2019 The Authors. This is an author-produced version of a paper subsequently published in *Microbiology*. Uploaded in accordance with the publisher's self-archiving policy.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

1 *Staphylococcus aureus* adaptation to aerobic low redox potential
2 environments: implications for an intracellular lifestyle

3

4 **Benjamin A. F. Christmas¹, Matthew D. Rolfe¹, Matthew Rose¹ and Jeffrey
5 Green^{1,*}**

6

7 **Author affiliations:** ¹The Florey Institute, Department of Molecular Biology and
8 Biotechnology, University of Sheffield, Sheffield S10 2TN, United Kingdom

9 ***Correspondence:** Jeffrey Green, jeff.green@sheffield.ac.uk

10 **Keywords:** aminoglycoside antibiotics; gene regulation; intracellular pathogen; MSRA;
11 redox-sensing; small colony variants

12 **Abbreviations:** CFUs, colony forming units; $\Delta\Psi$, membrane electrical potential; DTNB, 5, 5'-
13 dithiobis(2-nitrobenzoate); DTT, dithiothreitol; E_h , redox potential; GSH, glutathione; OD₆₀₀,
14 optical density at 600 nm; PDHC, pyruvate dehydrogenase; SCVs, small colony variants
15 Five supplementary figures are available with the online version of this article.

16

17 **Abstract**

18 Methicillin-resistant *Staphylococcus aureus* is a ‘superbug’, responsible for extensive death
19 and morbidity. Chronic *S. aureus* infections are associated with the presence of intracellular
20 bacteria and the host cytosol is an aerobic low redox potential (E_h) environment. How *S.*
21 *aureus* adapts to aerobic low E_h environments is understudied. A low external E_h , imposed
22 by the non-metabolizable reductant dithiothreitol, resulted in transcriptional reprogramming
23 mediated by the redox-responsive transcription factors AgrA, Rex and SrrBA resulting in a
24 shift towards fermentative metabolism. Accordingly, in the presence of the host cytoplasmic
25 reductant glutathione *S. aureus* aerobic respiration was impaired, the intracellular
26 NADH:NAD⁺ ratio increased, lactate dehydrogenase was induced, resistance to the
27 aminoglycoside antibiotic gentamicin was enhanced and greater numbers of small colony
28 variants (SCVs) were detected. These observations suggest that entry of *S. aureus* into the
29 aerobic low E_h environment of the host cytosol could result in adaptive responses that
30 promote the formation of SCVs.

31

32 **INTRODUCTION**

33 Methicillin-resistant *Staphylococcus aureus*, such as *S. aureus* USA300 JE2, is a ‘superbug’
34 that is resistant to a range of clinical antibiotics and a major healthcare problem. It is an
35 adaptable bacterium with a formidable armoury of virulence factors leading to a range of
36 clinical syndromes, including bacteremia, toxic shock syndrome, meningitis and pneumonia
37 [1]. Chronic, recurrent infections are often characterized by the presence of slow growing,
38 antibiotic-resistant small colony variants (SCVs) that have been associated with invasion of,
39 and survival within, non-professional phagocytes [2-10]. Stable (genotypic) SCVs are often
40 characterized by mutations in genes required for menaquinone or haem biosynthesis and
41 consequently exhibit impaired respiratory metabolism, resulting in phenotypes resembling
42 those observed in hypoxic environments [11]. Secondary mutations that constitutively

43 activate the redox-sensing two-component system SrrBA, which plays a major role in
44 adaption to hypoxic environments, permits stable SCVs to retain drug-resistance whilst
45 regaining the capacity for rapid growth [11]. In contrast, phenotypic SCVs are unstable and
46 revert to normal growth rates with loss of antibiotic resistance, suggesting a reversible
47 mechanism that avoids the permanent fitness costs of genotypic resistance [12]. Adoption of
48 the SCV phenotype within the confines of a host cell and reversion to wild-type virulence
49 traits within 24 h of liberation is thought to be a mainstream component of the process
50 leading to chronic infections [9,10].

51 The redox potential (E_h) of host cell cytoplasm is low (-220 to -285 mV) due the presence of
52 high (30:1 to 100:1) ratios of reduced glutathione (GSH) to oxidized glutathione (GSSG)
53 [13]. It is clear that *S. aureus* can survive and replicate in the host intracellular milieu
54 [9,10,14]. Therefore, the work reported here was undertaken to begin to improve
55 understanding of how *S. aureus* adapts to an aerobic low E_h environment, such as might be
56 encountered in the host cytosol. It is suggested that low E_h prompts *S. aureus* transcriptional
57 reprogramming mediated by redox-responsive transcription regulators, including Agr, Rex
58 and SrrA, resulting in induction of fermentative metabolism, lower growth rates, resistance to
59 aminoglycoside antibiotics and enhanced formation of SCVs. Hence adaptation to the low E_h
60 of the host cytosol could contribute to establishing and maintaining persistent infections.

61 **METHODS**

62 **General culture conditions**

63 The bacterial strains used were: *S. aureus* USA300 JE2 and the *S. aureus* USA300 JE2 *rex*
64 mutant from the Nebraska Tn library [15]; *S. aureus* RN4220 was the host for the *ldh1-gfp*
65 plasmid pGS2625 (see below) [16]. Standard culture conditions and growth media were as
66 described in Sambrook and Russell [17]. Appropriate antibiotics were added from sterile

67 stock solutions. Overnight liquid cultures were prepared from single colonies transferred into
68 5 ml of liquid medium (Brain Heart Infusion broth, Tryptic Soy broth or Luria-Bertani broth)
69 and incubated at 37°C with shaking (250 rpm). To estimate bacterial growth, optical density
70 was measured at 600 nm (OD₆₀₀) using an ATI Unicam spectrophotometer. To measure
71 viable bacterial cells, suspensions were serially diluted 1:10 in phosphate-buffered saline in
72 triplicate and then 10 µl of each dilution was spotted onto solid medium. The dried agar
73 plates were incubated at 37°C overnight and the number of colony forming units (CFUs) was
74 counted.

75 Growth in liquid media was also monitored using a Sunrise™ microplate reader (TECAN).
76 An overnight starter culture was diluted 1:50 into 50 ml fresh medium, as indicated for each
77 experiment, and after 3 h at 37°C with shaking (250 rpm) the culture was diluted to OD₆₀₀
78 0.0125 in 200 µl fresh medium (supplemented as indicated in the text) in the wells of a 96
79 well plate (Thermo Scientific). The plates were incubated at 37°C in the microplate reader
80 with shaking, where OD₆₀₀ was recorded every 15 min by the Magellan 7.1 software
81 (TECAN).

82 **Continuous cultures**

83 A single colony of *S. aureus* USA300 JE2 was used to inoculate 5 ml Brain Heart Infusion
84 broth for incubation overnight at 37°C with shaking (250 rpm). This culture was then injected
85 into a 2 l Labfors chemostat vessel (Infors-HT, Switzerland) containing 1 l of chemically
86 defined medium with 15 mM glucose as the sole source of carbon and 0.0001% (v/v)
87 Antifoam Y-30 Emulsion (Sigma-Aldrich) [18]. The culture was grown under batch
88 conditions for 5–20 h before being switched to continuous culture with a dilution rate of 0.2
89 h⁻¹. Positive dissolved oxygen concentrations were maintained by constant addition of filtered
90 air (1 l min⁻¹) and agitation (400 rpm). Temperature (37°C) and pH (7.0) were maintained

91 throughout the experiments. Redox potential (E_h) was measured using an ORP FermProbe
92 (Broadly James) according to the manufacturer's instructions. An E_h of 86 mV was set by
93 using a pH 7.0 Quinhydrone-buffered solution and an E_h of 263 mV was set by using a pH
94 4.0 Quinhydrone-buffered solution.

95 The aerobic steady-state cultures were perturbed by addition of 9.7 mM (final concentration)
96 dithiothreitol (DTT) directly to the culture and the feed supply. Samples, for transcript
97 profiling, enzyme assays, optical density measurements (OD_{600}) and 1H -NMR measurements
98 of exo-metabolites, were taken at 0, 2, 5, 10, 15, 30, 60 and 1440 min following the addition
99 of DTT.

100 Samples for RNA isolation were taken by collection directly into 2 volumes of RNAprotect
101 Bacteria Reagent (QIAgen). These were immediately mixed (vortexed for 5 s) and then
102 incubated at room temperature for 5 min before centrifugation ($4^\circ C$) for 10 min at 3,380 xg .
103 The supernatant was then poured off and the pellet suspended in the residual solution. The
104 suspended sample was then transferred to a 1.5 ml micro-centrifuge tube and centrifuged for
105 10 min at 20,000 xg before removing the supernatant and storing the pellet at $-80^\circ C$.

106 Samples (5 ml) for culture medium analysis were centrifuged ($4^\circ C$) for 10 min at 3,380 xg .
107 The supernatant was passed through a 0.22 μm syringe filter and two 1.5 ml samples were
108 stored in micro-centrifuge tubes at $-80^\circ C$.

109 Samples for enzyme assays were collected at 0, 60 and 1440 min following the addition of
110 DTT. Two 50 ml culture samples were collected in two 50 ml tubes and centrifuged in a
111 cooled centrifuge ($4^\circ C$) for 10 min at 3,380 xg . The supernatants were poured off and the
112 samples stored at $-80^\circ C$.

113 **Transcript profiling**

114 A custom Agilent microarray was designed using eArray (www.earray.chem.agilent.com). It
115 contained probes for *S. aureus* USA300_FPR3757 and *S. aureus* N8325 (Agilent Design ID:
116 066358). RNA labelling was achieved using 8 µg of purified RNA in 6.15 µl molecular
117 biology grade water and 2.5 µg of random primers (Invitrogen). This mixture was incubated
118 for 10 min at 72°C and then placed on ice for 10 min. Addition of 6.25 µl reverse
119 transcription mix (5x First strand buffer, 3.0 µl; 0.1 M DTT, 1.5 µl; 50x dNTP mix, 0.3 µl
120 (dNTP mix contained 25 mM dATP, dTTP, dGTP and 10 mM dCTP) and molecular biology
121 grade water, 1.45 µl) followed by 1 µl 1 mM Cy5-dCTP (or Cy3-dCTP for the time 0 min
122 reference samples) (GE Healthcare) and 0.75 µl SuperScript III reverse transcriptase (200 U
123 µl⁻¹, Invitrogen). The samples were incubated for 5 min at 25°C then overnight at 50°C before
124 addition of 7.5 µl 0.1 M NaOH and incubation for 10 min at 72°C, followed by addition of
125 7.5 µl of 0.1 M HCl. The samples were purified using PCR purification kit (Qiagen) and the
126 concentration of cDNA and labelling efficiency was measured using a Nanodrop™ (ND-
127 1000 Spectrophotometer, Peqlab Ltd). Hybridization and washing were carried out according
128 to the manufacturer's instructions (Agilent Two-Color Microarray-Based Prokaryotic
129 Analysis (Fairplay III Labeling) Protocol). Cy5-labelled cDNA (300 ng) from the test sample
130 was hybridized in tandem with 300 ng of Cy3-labelled cDNA from the 0 min (initial steady-
131 state) sample. The array slides were incubated at 65°C for 17 h in a Hybridisation Oven
132 (Agilent). Slides were scanned in an Agilent Microarray Scanner and data were extracted
133 from .tif files using Agilent Feature Extraction 11.5. Data were analyzed using Agilent
134 GeneSpring 7.3.1. Signal intensities for each array were divided by the signal obtained from
135 the control channel (Cy3-labelled time point 0 min) with a median shift being applied across
136 all samples included in each comparison. A Student's t-test (2 tailed, equal variance) with
137 Benjamini-Hochberg correction was applied to the data. The complete gene expression data
138 are available in ArrayExpress accession number E-MTAB-6942.

139 The TFinfer software was used to infer changes in the activities of 11 *S. aureus* transcription
140 factors (AirR, AgrA, CstR, CymR, MgrA, NreABC, Rex, Rot, SarA, SarZ and SrrA) [19].
141 TFinfer is a state space model representing a simplified version of transcription based on a
142 linear approximation (in log space) to the dynamics of transcription and treats noise in a
143 principled way such that the estimated TF activities are associated with confidence limits
144 [19]. The model was implemented using a connectivity matrix linking the 11 *S. aureus*
145 transcription factors listed above to genes present in their regulons as identified by transcript
146 profiles of parent and mutant strains and the time-resolved gene expression data for all the
147 genes present in the connectivity matrix.

148 **Detection of small colony variants (SCVs)**

149 A single colony of *S. aureus* USA300 JE2 or the isogenic *rex* mutant from the Nebraska Tn
150 mutant library [15] (confirmed by PCR) was used to inoculate 5 ml of Tryptic Soy broth and
151 then incubated overnight at 37°C with shaking (250 rpm). This culture was used to inoculate
152 50 ml fresh medium to OD₆₀₀ 0.05. After 3 h incubation at 37°C with shaking (250 rpm) GSH
153 (10 mM) was added and the culture was incubated for a further hour. Then the culture was
154 serially diluted 1:10 in triplicate and 10 µl spotted onto plates (Tryptic Soy agar) with and
155 without GSH (10 mM) and with and without gentamicin (2 µg ml⁻¹). After 48 h the colony
156 forming units were counted and the SCVs were assigned based on appearance: small (~10th
157 size of wild-type colonies), light-coloured (white or pale yellow as compared to orange wild-
158 type colonies) and gentamicin-resistant.

159 **Lactate dehydrogenase assay**

160 Aliquots of cell-free extracts (~20 ng protein) were added to 35 mM Tris-HCl, pH 7.9
161 containing 1 mM MnSO₄ and 0.15 mM NADH and absorbance at 340 nm was monitored
162 using a spectrophotometer at 37°C. After establishing a base rate, pyruvate (5 mM) was

163 added and the oxidation of NADH was monitored at 340 nm. The specific activity of lactate
164 dehydrogenase was calculated in $\mu\text{mol NADH oxidized mg}^{-1} \text{ h}^{-1}$ using a molar extinction
165 coefficient for NADH of $6,220 \text{ M}^{-1} \text{ cm}^{-1}$.

166 **Construction and assay of a *ldh1-gfp* promoter fusion plasmid**

167 The intergenic region between *ldh1* and the divergent *SAUSA300_0234* gene was amplified
168 from genomic DNA using PCR primers containing *KpnI* and *HindIII* restriction enzyme sites.
169 The PCR product and the reporter plasmid, pCM20, which contains the *S. aureus nuc*
170 promoter fused to superfolder *gfp*, were digested with *KpnI* and *HindIII* to release the *nuc*
171 promoter from pCM20 and prepare the *ldh1* promoter region for ligation upstream of *gfp*
172 [20]. After gel purification (Qiagen Gel Extraction kit), the *ldh1* promoter and the pCM20
173 plasmid backbone were ligated. The ligation mixes were used to transform competent *E. coli*
174 cells and the transformants were selected by plating on agar plates containing ampicillin (100
175 $\mu\text{g ml}^{-1}$). The authenticity of the construct (pGS2625) was confirmed by DNA sequencing
176 before transferring the plasmid to *S. aureus* RN2440 by selecting for growth on erythromycin
177 ($4 \mu\text{g ml}^{-1}$).

178 **Pyruvate dehydrogenase assay**

179 Pyruvate dehydrogenase complex activity was estimated by measuring the rate of depletion
180 of CoASH in a discontinuous assay. Cell extracts of bacteria grown as Brain Heart Infusion
181 broth batch cultures were prepared by two passages through a French pressure cell. A
182 reaction mixture containing buffer (31 mM Tris-HCl, pH 8.5), thiamine pyrophosphate (0.33
183 mM), cell-free extract, CoASH (0.08 mM), NAD^+ (3 mM) and NADH (0-3 mM) was
184 prepared. The reaction was initiated with the addition of pyruvate (11.5 mM) and stopped
185 after 10 min using 10% SDS before adding 5, 5' dithiobis(2-nitrobenzoate) (DTNB) (0.04%).
186 The amount of CoASH remaining was calculated by measuring absorbance at 412 nm on an

187 ATI Unicam UV/VIS spectrophotometer using the molar extinction coefficient for 2-
188 nitrothiobenzoate ($13,700 \text{ M}^{-1} \text{ cm}^{-1}$).

189 **Respiration rate measurements**

190 Oxygen uptake rates at 37°C of washed cell suspensions were measured using a Clark-type
191 oxygen electrode (Rank Bros Ltd). Overnight cultures were diluted 1:50 in 50 ml fresh
192 medium incubated for 3 h at 37°C with shaking (250 rpm) to produce log phase cultures.
193 These bacteria were collected by centrifugation (4°C) for 10 min at $3,380 \times g$. The cell pellets
194 were suspended in pre-cooled 0.02 M phosphate-buffered saline and centrifuged in a cooled
195 centrifuge (4°C) for 10 min at $3,380 \times g$ twice before the resulting washed cell pellets were
196 suspended in pre-cooled 0.02 M phosphate-buffered saline to a final optical density (OD_{600})
197 of 50. Aliquots ($50 \mu\text{l}$) of the cell suspension were added to phosphate-buffered saline (1950
198 μl) and after the baseline rate of oxygen uptake was established, glucose (2.5 mM final
199 concentration) was injected. After 1 min either a control of $50 \mu\text{l}$ 0.02 M phosphate-buffered
200 saline was added or $50 \mu\text{l}$ KCN (final concentration 25 mM) or GSH (final concentration 10
201 mM). Respiration rates ($\text{nmol O}_2 \text{ min}^{-1} \text{ OD}_{600}^{-1}$) were then calculated.

202 **Growth inhibition zone assay**

203 An overnight culture was diluted 1:100 in 20 ml of molten (50°C) soft agar (0.7% agar)
204 Tryptic Soy medium. This was then poured onto 20 ml solid Tryptic Soy medium and left to
205 cool before a sterile 6 mm filter paper disc was placed on top. The disc was loaded with $20 \mu\text{l}$
206 of gentamicin (50 mg ml^{-1}) and the plates were incubated at 37°C overnight under aerobic or
207 anaerobic (anaerobic jars which contained an Oxoid AnaeroGen 2.5 L sachet) conditions
208 before measurement of the growth inhibition zone. In other experiments Tryptic Soy medium
209 was replaced by chemically defined medium with and without nitrate (10 mM) [18].

210 **Measurement of NADH:NAD⁺ ratios**

211 A single colony from solid medium was used to inoculate a 5 ml chemically defined medium
212 supplemented with 10% Luria-Bertani broth overnight at 37°C with shaking (250 rpm). This
213 was used to inoculate the same medium (50 ml), which was incubated (37°C, 250 rpm
214 shaking) to OD₆₀₀ ~1.0. Two samples (5 ml) were removed from the culture and GSH (10
215 mM) was added to the culture, which was incubated for a further hour before taking further 5
216 ml samples. All samples taken were immediately placed within pre-cooled (-80°C) 50 ml
217 tubes. The cells were collected by centrifugation and washed in M9 salts before storing at -
218 20°C. For NAD⁺ extraction, pellets were suspended in 0.2 M HCl and sonicated for two 30 s
219 bursts. The sample was then centrifuged, the pellet was discarded and the supernatant was
220 neutralized with 0.2 M NaOH. The same method was employed for NADH extraction, except
221 that 0.2 M NaOH was initially added to suspend the cell pellets before sonication and 0.2 M
222 HCl was used to neutralize the supernatant after centrifugation. The cell extracts obtained
223 were then used in the coupled assay of Bernofsky and Swan [21]. Reactions contained: 0.144
224 M glycylglycine, pH 7.0; 0.035% ethanol; 2.4 mM phenazine ethosulfate; 0.6 mM
225 methylthiazolyldiphenyl-tetrazolium bromide; 500 µl cell-extract; and H₂O to 995 µl.
226 Reaction mixtures were left to equilibrate in the dark for 20 min before being started with the
227 addition of yeast alcohol dehydrogenase (5 µl; 9-18 units µl; Roche). The reactions were
228 followed spectrophotometrically at 570 nm.

229

230 **RESULTS AND DISCUSSION**

231 **An aerobic low E_h environment induces fermentative metabolism in cultures of**
232 ***S. aureus* USA300 JE2**

233 In the first phase of this work the non-metabolizable reducing agent dithiothreitol (DTT; E_h -
234 330 mV at pH 7.0) was used to isolate the effects of low external E_h from other potentially
235 confounding factors that might arise from using a metabolically active physiological
236 reductant. Aerobic steady-state chemostat cultures of *S. aureus* USA300 JE2 (triplicate
237 independent cultures; pH 7.0, dilution rate 0.2 h^{-1} , dissolved O_2 in the medium $\geq 10\%$) were
238 established. After baseline sampling, the steady-states were perturbed by introducing DTT
239 (9.7 mM) to mimic the low external E_h in the aerobic but reducing environment of the host
240 cell cytoplasm (the maximum growth rate of *S. aureus* USA300 JE2 in batch cultures
241 containing 9.7 mM DTT was greater than the growth rate set by the dilution rate of the
242 chemostat; Fig. S1). The external E_h of the initial steady-state cultures was 60 ± 14 mV,
243 similar to previous reports (~ 50 mV) [22], but after addition of DTT rapidly decreased to a
244 final value of $\sim -275 \pm 40$ mV (Fig. 1a). The dissolved O_2 concentration in the culture
245 increased rapidly after DTT addition, before returning to the pre-perturbation value at 30 min
246 consistent with a transient decrease in respiration rate (Fig. 1b). After perturbation the
247 concentration of excreted lactate increased ~ 6 -fold from ~ 1 mM to 6.2 ± 0.1 mM in the new
248 low E_h steady-state, indicating that $\sim 20\%$ of glucose carbon supplied was converted to lactate
249 under these new conditions (Fig. 1c). Accordingly, the lactate dehydrogenase activity of cell-
250 free extracts increased ~ 6 -fold after 60 min and ~ 14 -fold 1440 min after exposure to DTT
251 (Fig. 1d). These data suggest that when *S. aureus* enters a low E_h aerobic environment,
252 aerobic respiration is transiently inhibited (manifest as a decrease in O_2 consumption) and
253 aerobic respiratory metabolism and fermentation co-exist (respiro-fermentative growth).

254

255 **An aerobic low E_h environment triggers *S. aureus* USA300 JE2 transcriptional**
256 **reprogramming consistent with a shift to respiro-fermentative metabolism**

257 The dynamics of *S. aureus* USA300 JE2 gene expression in response to perturbation of the
258 external redox state were measured by time-resolved transcript profiling (Table 1). TFInfer is
259 a state space model that reveals the changes in transcription factor activities that drive
260 transcriptional reprogramming [19]. A connectivity matrix was assembled for 11 *S. aureus*
261 transcription factors (AirR, AgrA, CstR, CymR, MgrA, NreABC, Rex, Rot, SarA, SarZ and
262 SrrA) that have previously been associated with redox-sensing and/or persistence [23-32].
263 Inference of the activities of these 11 transcription factors predicted that Rex and SrrA
264 exhibited the greatest changes (≥ 7 -fold, $\geq 90\%$ confidence; Fig. 1e). DNA-binding by Rex is
265 impaired when the NADH:NAD⁺ ratio is high, resulting in derepression of genes associated
266 with anaerobic metabolism. A reduced quinone pool activates the SrrBA two-component
267 system resulting in activation of genes involved in anaerobic metabolism, cytochrome and
268 heme biosynthesis and down-regulation of *agr*-RNAIII. This is consistent with the strong
269 induction of transcripts associated with anaerobic metabolism: *pflBA*, *ldh1*, *adh*, *narG*, and
270 *ddh* (Table 1). Previous work has shown enhanced abundance of fermentative enzymes
271 pyruvate formate lyase (PflB), alcohol dehydrogenase (Adh), D- and L-lactate
272 dehydrogenases (Ddh, Ldh1, Ldh2; the latter being maximally up-regulated 9.1-fold in
273 response to DTT and hence just below the 10-fold cut-off applied to genes listed in Table 1)
274 [33]. Moreover, *S. aureus* Newman strain *ldh1* and *ldh1-ldh2* double mutants are
275 significantly attenuated in a mouse model of infection [34]. Taken together these analyses
276 suggest that redox-sensing and induction of fermentative metabolism are important factors
277 for intracellular survival of *S. aureus*.

278 The TFInfer analysis also suggested that AgrA activity decreased under low E_h
279 conditions, manifest as severe down-regulation of the *agr* locus and lower expression of
280 *psmB1*, *psmB2* and *hld* (Fig. 1e; Table 1). Down-regulation of the Agr-activated *psmB1* and
281 *psmB2*, coding for the phenol soluble modulins PSMB1 and PSMB2, is a major factor in *S.*

282 *aureus* persister formation, and the δ -toxin (*hld*, PSM γ) is implicated in phagosome escape
283 [35,36].

284

285 **The host cytoplasmic reductant glutathione increases the frequency of *S.***
286 ***aureus* USA300 JE2 SCVs and enhances resistance to gentamicin**

287 The experiments using DTT as an extracellular reductant indicated that *S. aureus* USA300
288 JE2 responded to an aerobic low E_h environment by adopting respiro-fermentative
289 metabolism. The host cytosol is an aerobic low E_h environment maintained by the reductant
290 GSH. The experiments using DTT suggested that exposing *S. aureus* USA300 JE2 to GSH
291 (10 mM) would result in impaired respiration and this was found to be the case (Fig. 2a).
292 Impairment of respiration was found to be associated with higher NADH:NAD⁺ ratios (Fig.
293 S2). Higher NADH:NAD⁺ ratios are known to inhibit pyruvate dehydrogenase (PDHC)
294 activity in several bacterial species and measurement of *S. aureus* USA300 JE2 PDHC
295 activity showed that it was also inhibited at elevated NADH:NAD⁺ ratios (Fig. S3) [37].
296 Consistent with these observations and the enhanced expression of *ldh1* after perturbation of
297 the chemostat cultures by DTT (Table 1), expression of Green fluorescent protein from a
298 plasmid borne (pGS2625) *ldh1-gfp* fusion in *S. aureus* RN4220 was increased in the presence
299 of GSH (Fig. 2b). This is interpreted as indicating sensing of increased NADH:NAD⁺ ratio
300 by the transcription factor Rex leading to derepression of *ldh1* and consequent reduction of
301 pyruvate to lactate.

302 A *S. aureus* membrane electrical potential ($\Delta\Psi$) of -75 to -95 mV is required for uptake of the
303 aminoglycoside antibiotic gentamicin [38]. Bacteria adopting respiro-fermentative
304 metabolism are likely to have a lower $\Delta\Psi$ compared to those utilizing aerobic respiration and
305 therefore the resistance of *S. aureus* USA300 JE2 to gentamicin was tested in the presence of
306 GSH. Addition of GSH to the culture medium allowed *S. aureus* USA300 JE2 to grow in the

307 presence of gentamicin (Fig. 2c). The ionophore, nigericin, is capable of restoring $\Delta\Psi$ at the
308 expense of the transmembrane proton gradient. Addition of nigericin to low E_h cultures of *S.*
309 *aureus* USA300 JE2 partially restored sensitivity to gentamicin (Fig. 2d). The increased
310 resistance to gentamicin in the presence of GSH is therefore likely caused by a decrease in
311 $\Delta\Psi$. Accordingly, gentamicin tolerance correlated with the E_h of the electron acceptor being
312 used to support growth, i.e. *S. aureus* USA300 JE2 growing by aerobic respiration was less
313 tolerant to gentamicin than when growing by anaerobic (nitrate) respiration or by anaerobic
314 fermentation and this aerobic sensitivity was much diminished in the presence of GSH (Fig.
315 2e and f).

316 As noted above, *S. aureus* SCVs are induced by the host intracellular environment in which
317 the bacteria are exposed to the cytoplasmic reductant GSH. Plating *S. aureus* USA300 JE2
318 under aerobic conditions in the presence of GSH resulted in a significant increase in the
319 number of SCVs, suggesting that the adaptations initiated by perception of the low E_h signal
320 contribute establishing the SCV phenotype (Fig. 2g; closed bars). One plausible explanation
321 for the increased frequency of *S. aureus* USA300 JE2 SCVs in the presence of GSH was that
322 mutation rates were greater under reducing conditions. However, measurements indicated
323 that there was no significant difference (2-tailed T-test $p= 0.39$) in the frequencies of
324 rifampicin ($100 \mu\text{g ml}^{-1}$) resistant mutants in the absence ($1.3 \times 10^{-7} \pm 0.7 \times 10^{-7}$; $n=3$) or
325 presence ($6.8 \times 10^{-8} \pm 3.8 \times 10^{-8}$; $n=3$) of GSH (10 mM).

326 The transcriptional profiling and associated prediction of transcription factor activities
327 indicated major changes in the regulation of the Rex regulon under low E_h conditions (Table
328 1). Therefore, SCV formation by the *S. aureus* USA300 JE2 *rex* mutant, from the Nebraska
329 Tn library, was measured in the presence and absence of GSH. The frequency of *rex* mutant
330 SCVs from cultures pre-exposed to GSH (10 mM) was similar to that of unexposed cultures
331 when plated on Tryptic Soy agar containing gentamicin ($2 \mu\text{g ml}^{-1}$) (Fig. 2f, open bars) and

332 greater than that observed for the parent strain. When the *rex* mutant was spread on plates
333 containing gentamicin ($2 \mu\text{g ml}^{-1}$) and GSH (10 mM) bacterial lawns were observed for both
334 pre- and un-treated cultures, suggesting that in the presence of GSH the *rex* mutant exhibits
335 increased resistance to gentamicin. Accordingly, the frequency of *rex* mutant SCVs in the
336 presence of GSH (10 mM) and a higher concentration of gentamicin ($10 \mu\text{g ml}^{-1}$) was greater
337 than that observed when the plates contained the standard concentration of gentamicin ($2 \mu\text{g}$
338 ml^{-1}) and no GSH (Fig. 2f, open bars). It was concluded that derepression of anaerobic
339 metabolism by deletion of *rex* enhances SCV formation and that the *rex* mutant exhibits
340 enhanced tolerance to gentamicin in the presence of GSH compared to the parent strain under
341 these conditions.

342 These data suggested that GSH increased the frequency of *S. aureus* USA300 JE2 SCVs
343 without significantly increasing the frequency of general mutation. Therefore, phenotypic
344 stability of *S. aureus* USA300 JE2 SCVs in the absence and presence of GSH (10 mM) was
345 determined. Small colony variants were first generated by plating aliquots of overnight
346 Tryptic Soy broth cultures on Tryptic Soy agar supplemented with gentamicin ($2 \mu\text{g ml}^{-1}$) and
347 incubating at 37°C for 48 h [39]. Small colony variants were picked and sequentially patched
348 onto Tryptic Soy agar supplemented with GSH (10 mM) and unamended Tryptic Soy agar.
349 After incubation at 37°C for 3 days the patches were scored as unstable, mixed or stable as
350 defined by Edwards [39] (Fig. S4). Examination of 210 SCVs indicated that 66 of these
351 acquired a mixed phenotype when plated on Tryptic Soy agar but retained a stable SCV
352 phenotype on Tryptic Soy agar containing GSH (Table 2). Thirteen SCVs with an unstable
353 phenotype on Tryptic Soy agar exhibited either a stable or mixed phenotype in the presence
354 of GSH (Table 2). Thus, as well as increasing the frequency of SCVs, GSH appears to
355 support the retention of the SCV phenotype.

356

357 **Concluding remarks**

358 Investigation of *S. aureus* adaptation to aerobic low E_h environments revealed a remodelling
359 of central metabolism linked to changes in the activities of the redox-responsive transcription
360 factors AgrA, Rex and SrrA (Fig. 3). The data reported here suggest that aerobic low E_h
361 environments, such as the host cytosol, switch off AgrA, probably via leakage of electrons
362 from reduced flavins and quinones to O_2 , creating reactive oxygen species that promote
363 formation of an intramolecular disulfide bond in the DNA-binding domain of AgrA [40]. A
364 more reduced electron transport chain would activate SrrA, which allows stable SCVs to
365 retain drug-resistance whilst regaining the capacity for rapid growth [11]. The increased
366 NADH:NAD⁺ ratios found under aerobic low E_h conditions impair DNA-binding by Rex,
367 causing derepression of genes associated with fermentative metabolism. Reducing
368 environments, that mimic the redox potential of the host cytoplasm, activate the virulence
369 program of the intracellular pathogen *Listeria monocytogenes* and it was suggested that this
370 might be explained, at least in part, by alteration in NADH:NAD⁺ balance leading to Rex-
371 mediated transcriptional reprogramming [41]. The evidence presented here indicates that
372 redox-sensing and de-repression of Rex-regulated genes signalled by increased NADH:NAD⁺
373 ratios is a major component of the adaptive response of *S. aureus* to an aerobic low E_h
374 environment (Fig. 3). Hence Rex-mediated transcriptional reprogramming might be a
375 common feature promoting the survival of Gram-positive pathogens in the host cytosol. The
376 increased frequency of SCVs in the presence of GSH implies that intracellular *S. aureus*
377 residing in the aerobic low E_h environment of the host cytoplasm is one possible source of
378 phenotypic SCVs associated with difficult to treat infections. It is anticipated that these
379 observations will prompt further work to better understand the role of the low E_h of the host
380 cytosol in establishing and maintaining persistent infections by facultative and obligate
381 intracellular pathogens.

382

383 **References**

- 384 1. Tong SYC, Davis JS, Eichenberger E, Holland TL, Fowler, VG. *Staphylococcus aureus*
385 infections: epidemiology pathophysiology clinical manifestations and management. *Clin*
386 *Microbiol Rev* 2015;28:603-661.
- 387 2. Allison KR, Brynildsen MP, Collins, JJ. Metabolite-enabled eradication of bacterial
388 persisters by aminoglycosides. *Nature* 2011;473:216-220.
- 389 3. Kim, NH *et al.* Small-colony variants in persistent and recurrent *Staphylococcus aureus*
390 bacteremia. *Microb Drug Resist* 2016;22:538-544.
- 391 4. Löffler B, Tuchscher L, Niemann S, Peters, G. *Staphylococcus aureus* persistence in non-
392 professional phagocytes. *Int J Med Microbiol* 2014;304:170-176.
- 393 5. Sendi P, Proctor RA. *Staphylococcus aureus* as an intracellular pathogen: the role of small
394 colony variants. *Trends Microbiol* 2009;17:54-58.
- 395 6. Vesga O, Groeschel MC, Otten MF, Brar DW, Vann, JM *et al.* *Staphylococcus aureus*
396 small colony variants are induced by the endothelial cell intracellular milieu. *J Infect Dis*
397 1996;173:739-742.
- 398 7. Proctor RA, van Langevelde P, Kristjansson M, Maslow JN, Arbeit RD. Persistent and
399 relapsing infections associated with small colony variants of *Staphylococcus aureus*.
400 *Clinic Infect Dis* 1995;20:95-102.
- 401 8. von Eiff C, Becker K, Metze D, Lubritz G, Hockmann J *et al.* Intracellular persistence of
402 *Staphylococcus aureus* small-colony variants within keratinocytes: a cause for antibiotic
403 treatment failure in a patient with Darier's disease. *Clin Infect Dis* 2001;32:1643-1647.
- 404 9. Tuchscher L, Heitmann V, Hussain M, Viemann D, Roth J *et al.* *Staphylococcus aureus*
405 small-colony variants are adapted phenotypes for intracellular persistence. *J Infect Dis*
406 2010;202:1031-1040.
- 407 10. Tuchscher L, Medina E, Hussain M, Völker W, Heitmann V *et al.* *Staphylococcus aureus*
408 phenotype switching: an effective bacterial strategy to escape host immune response
409 and establish a chronic infection. *EMBO Mol Med* 2011;3:129-141.
- 410 11. Cao S, Huseby DL, Brandis G, Hughes D. Alternative evolutionary pathways for drug-
411 resistant small colony variant mutants in *Staphylococcus aureus*. *mBio* 2017;8:e00358-
412 17.
- 413 12. Massey RC, Buckling A, Peacock SJ. Phenotypic switching of antibiotic resistance
414 circumvents permanent costs in *Staphylococcus aureus*. *Current Biology* 2001;11:1810-
415 1814.
- 416 13. Hwang C, Sinskey AJ, Lodish HF. Oxidized redox state of glutathione in the endoplasmic
417 reticulum. *Science* 1992;257:1496-1502.

- 418 14. Grosz M, Kolter J, Paprotka K, Winkler AC, Schäfer D *et al.* Cytoplasmic replication of
419 *Staphylococcus aureus* upon phagosomal escape triggered by phenol-soluble modulins α .
420 *Cell Microbiol* 2016;16:451-465.
- 421 15. Fey PD, Endres JL, Yajjala VK, Widhelm TJ, Boissy RJ *et al.* A genetic resource for rapid
422 and comprehensive phenotype screening of nonessential *Staphylococcus aureus* genes.
423 *mBio* 2013;4:e00537-12.
- 424 16. Nair D, Memmi G, Hernandez D, Bard J, Beaume M *et al.* Whole-genome sequencing of
425 *Staphylococcus aureus* strain RN4220, a key laboratory strain used in virulence
426 research, identifies mutations that affect not only virulence factors but also the fitness of
427 the strain. *J Bacteriol* 2011;193:2332-2335.
- 428 17. Sambrook J, Russell DW. *Molecular Cloning a Laboratory Manual* (2001) Cold Spring
429 Harbor Press, Cold Spring Harbor, New York.
- 430 18. Lithgow JK, Hayhurst EJ, Cohen G, Aharonowitz Y, Foster, SJ. Role of a cysteine
431 synthase in *Staphylococcus aureus*. *J Bacteriol* 2004;186:1579-1590.
- 432 19. Asif HMS, Rolfe MD, Green J, Lawrence ND, Rattray M *et al.* TFInfer: a tool for
433 probabilistic inference of transcription factor activities. *Bioinformatics* 2010;26:2635-
434 2636.
- 435 20. Kiedrowski MR, Kavanaugh JS, Malone CL, Mootz JM, Voyich JM, *et al.* Nuclease
436 modulates biofilm formation in community-associated Methicillin-resistant
437 *Staphylococcus aureus*. *PLoS ONE* 2011;6:e26714.
- 438 21. Bernofsky C, Swan M. An improved cycling assay for nicotinamide adenine dinucleotide.
439 *Anal Biochem* 1973;53:452-458.33.
- 440 22. Nouaille S, Rault L, Jeanson S, Loubière P, Le Loir Y *et al.* Contribution of *Lactococcus*
441 *lactis* reducing properties to the downregulation of a major virulence regulator in
442 *Staphylococcus aureus* the *agr* system. *Appl Environ Microbiol* 2014;80:7028-7035.
- 443 23. Chen PR, Nishida S, Poor CB, Cheng A, Bae T *et al.* A new oxidative sensing and
444 regulation pathway mediated by the MgrA homologue SarZ in *Staphylococcus aureus*.
445 *Molec Microbiol* 2009;71:198-211.
- 446 24. Dunman PM, Murphy E, Haney S, Palacios D, Tucker-Kellogg G *et al.* Transcription
447 profiling-based identification of *Staphylococcus aureus* genes regulated by the *agr*
448 and/or *sarA* loci. *J Bacteriol* 2001;183:7341-7353.
- 449 25. Grosseohme N, Kehl-Fie TE, Ma Z, Adams KW, Cowart DM *et al.* Control of copper
450 resistance and inorganic sulfur metabolism by paralogous regulators in *Staphylococcus*
451 *aureus*. *J Biol Chem* 2011;286:13522-13531.
- 452 26. Kinkel TL, Roux CM, Dunman PM, Fang FC. The *Staphylococcus aureus* SrrAB two-
453 component system promotes resistance to nitrosative stress and hypoxia. *mBio*
454 2013;4:e00696-13.

- 455 27. Luong TT, Dunman PM, Murphy E, Projan SJ, Lee, CY. Transcription profiling of the
456 MgrA regulon in *Staphylococcus aureus*. *J Bacteriol* 2006;188:1899-1910.
- 457 28. Pagels M, Fuchs S, Pané-Farré J, Kohler C, Menschner L *et al*. Redox sensing by a Rex-
458 family repressor is involved in the regulation of anaerobic gene expression in
459 *Staphylococcus aureus*. *Molec Microbiol* 2010;76:1142-1161.
- 460 29. Said-Salim B, Dunman PM, McAleese FM, Macapagal D, Murphy E *et al*. Global
461 regulation of *Staphylococcus aureus* genes by Rot. *J Bacteriol* 2003;185:610-619.
- 462 30. Schlag S, Fuchs S, Nerz C, Gaupp R, Engelmann S *et al*. Characterization of the
463 oxygen-responsive NreABC regulon of *Staphylococcus aureus*. *J Bacteriol*
464 2008;190:7847-7858.
- 465 31. Soutourina O, Poupel O, Coppée JY, Danchin A, Msadek T *et al*. CymR the master
466 regulator of cysteine metabolism in *Staphylococcus aureus* controls host sulphur source
467 utilization and plays a role in biofilm formation. *Molec Microbiol* 2009;73:194-211.
- 468 32. Sun F, Ji Q, Jones MB, Deng X, Liang H *et al*. AirSR, a 2Fe-2S cluster-containing two-
469 component system, mediates global oxygen sensing and redox signaling in
470 *Staphylococcus aureus*. *J Am Chem Soc* 2012;134:305-314.
- 471 33. Surmann K, Michalik S, Hildebrandt P, Gierok P, Depke M *et al*. Comparative proteome
472 analysis reveals conserved and specific adaptation patterns of *Staphylococcus aureus*
473 after internalization by different types of human non-professional phagocytic host cells.
474 *Front Microbiol* 2014;5:392.
- 475 34. Richardson AR, Libby SJ, Fang, FC. A nitric oxide-inducible lactate dehydrogenase
476 enables *Staphylococcus aureus* to resist innate immunity. *Science* 2008;319:1672-1676.
- 477 35. Giese B, Glowinski F, Paprotka K, Dittmann S, Steiner T *et al*. Expression of delta-toxin
478 by *Staphylococcus aureus* mediates escape from phago-endosomes of human epithelial
479 and endothelial cells in the presence of beta-toxin. *Cell Microbiol* 2011;13:316-329.
- 480 36. Xu T, Wang XY, Cui P, Zhang YM, Zhang WH *et al*. The Agr quorum sensing system
481 represses persister formation through regulation of phenol soluble modulins in
482 *Staphylococcus aureus*. *Front Microbiol* 2017;8:2189.
- 483 37. Snoep JL, de Graef MR, Westphal AH, de Kok A, Teixeira de Mattos MJ *et al*.
484 Differences in sensitivity to NADH of purified pyruvate dehydrogenase complexes of
485 *Enterococcus faecalis* *Lactococcus lactis* *Azotobacter vinelandii* and *Escherichia coli*:
486 implications for their activity *in vivo*. *FEMS Microbiol Lett* 1993;114:279-283.
- 487 38. Mates SM, Eisenberg ES, Mandel LJ, Patel L, Kaback R *et al*. Membrane potential and
488 gentamicin uptake in *Staphylococcus aureus*. *Proc Natl Acad Sci USA* 1982;79:6993-
489 6997.
- 490 39. Edwards AM. Phenotype switching is a natural consequence of *Staphylococcus aureus*
491 replication. *J Bacteriol* 2012;194:5404-5412.

- 492 40. Sun F, Liang H, Kong X, Xie S, Cho H *et al.* Quorum-sensing *agr* mediates bacterial
493 oxidation response via an intramolecular disulfide redox switch in the response regulator
494 AgrA. *Proc Natl Acad Sci USA* 2012;109:9095-9100.
- 495 41. Portman JL, Dubensky SB, Peterson BN, Whiteley AT, Portnoy DA. Activation of the
496 *Listeria monocytogenes* virulence program by a reducing environment. *mBio*
497 2017;8:e01595-17.

498 **Acknowledgments**

499 This work was supported by a University of Sheffield Florey Institute PhD scholarship to
500 B.A.F.C. We thank Prof. R.K. Poole, Dr. H. Southam for granting access to equipment (plate
501 reader and oxygen electrode instruments) and Dr. A. Wood for *S. aureus* strains and advice
502 on transformation protocols.

503 **Author contributions**

504 J.G. conceived the study and supervised the work. B.A.F.C., M.D.R. and M.R. carried out
505 the research; all authors contributed to analyzing the data and writing the manuscript.

506 **Conflict of interest**

507 The authors declare that there are no conflicts of interest.

508

509 **Figure legends**

510 **Fig. 1.** *Staphylococcus aureus* USA300 JE2 adapts to an aerobic low redox potential (E_h)
511 environment imposed by dithiothreitol (DTT) by adopting respiro-fermentative metabolism.
512 (a-e) Steady-state cultures (1 l) of *S. aureus* USA300 JE2 were maintained in chemically
513 defined medium at 37°C and pH 7.0 with constant aeration at 1 l min⁻¹ and a dilution rate of
514 0.2 l h⁻¹ before perturbation (at time zero) with 9.7 mM DTT. (a) Changes in redox potential.
515 (b) Changes in dissolved oxygen concentration. (c) Proton-NMR measurements of lactate
516 concentration in culture supernatants. (d) Lactate dehydrogenase activity of cell-free
517 extracts. All data shown in these panels are mean values \pm standard deviation from three
518 independent experiments. (e) Changes in transcription factor activities in response to
519 lowering the redox potential of *S. aureus* cultures were predicted using the TFinfer model
520 [19]. The input data were the fold changes in expression relative to the initial steady-state
521 for all the genes present in a binary connectivity matrix that linked 11 transcription factors
522 (see text) to directly- or indirectly-regulated genes. The output of the model is a time-
523 resolved series of transcription factor activities that could account for the observed changes
524 in gene expression. The activity of SrrA (circles) was predicted to increase after perturbation,
525 whereas the activities of AgrA (squares) and Rex (diamonds) were predicted to decrease.
526

527 **Fig. 2.** The host cytoplasmic reductant glutathione (GSH) inhibits *S. aureus* USA300 JE2
528 aerobic respiration, enhances tolerance to gentamicin and increases the frequency of small
529 colony variant (SCV) formation. (a) Respiratory activity of suspensions of *S. aureus* in
530 phosphate-buffered saline (PBS) in a chamber fitted with Clark-type oxygen electrode was
531 stimulated by the addition of glucose (25 mM; arrow g). Oxygen consumption was followed
532 and then either potassium cyanide (KCN, 25 mM; light blue trace) or GSH (10 mM; red
533 trace) were added and the inhibition of respiration relative to suspensions to which
534 phosphate-buffered saline was added (black trace) was calculated. Treatment with GSH (10
535 mM) inhibited the rate of oxygen uptake by 32 \pm 8%. The data shown are representative of

536 three independent experiments. (b) Induction of *ldh1* in the presence of GSH.
537 *Staphylococcus aureus* RN4220 was transformed with pGS2625, which carries the
538 superfolder *gfp* gene under the control of the *S. aureus* USA300 JE2 *ldh1* promoter. Aerobic
539 batch cultures of the reporter strain were grown in Tryptic Soy broth supplemented with 0.5%
540 glucose for 3 h at 37°C before addition of GSH (50 mM); control cultures were left untreated.
541 After overnight incubation, bacteria were washed and suspended to constant OD₆₀₀ and
542 GFP was detected by scanning fluorescence spectroscopy. Typical spectra (GFP emission
543 at 510 nm; excitation wavelength 485 nm) from triplicate experiments of suspension buffer
544 (blue trace), untreated cell suspensions (red trace) and GSH-treated cell suspensions (green
545 trace) are shown. (c) Growth of *S. aureus* USA300 JE2 in Luria-Bertani broth (blue trace),
546 Luria-Bertani broth supplemented with GSH (10 mM; grey trace), Luria-Bertani broth
547 supplemented with gentamicin (32 µg ml⁻¹; brown trace) and Luria-Bertani broth
548 supplemented with both (black trace). (d) Restoration of membrane electrical potential
549 antagonizes GSH-conferred gentamicin tolerance. Batch cultures of *S. aureus* USA300 JE2
550 were grown in triplicate in chemically defined medium containing gentamicin (2 µg ml⁻¹) in
551 shaking 96-well plates at 37°C. The medium was supplemented with GSH (10 mM; blue
552 trace), nigericin (2 nM; orange trace), or both (black trace). The data shown are mean optical
553 densities (OD₅₉₅) ± standard deviation for three cultures. (d and e) *Staphylococcus aureus*
554 USA300 JE2 metabolic mode affects tolerance to gentamicin. Chemically defined medium
555 agar plates with glucose (15 mM) as the carbon source with and without nitrate (10 mM)
556 were prepared and soft agar of matching medium seeded with *S. aureus* were overlaid on
557 the plates. Gentamicin (1 mg) was loaded on a central disc and the plates were incubated at
558 37°C for 24 h before measuring the zones of inhibition (arrows). The images shown are
559 representative of three experiments. (e) Plates incubated under: aerobic conditions – aerobic
560 respiratory growth (left); anaerobic conditions plus nitrate – anaerobic respiratory growth
561 (middle); anaerobic conditions – fermentative growth (right). (f) Plates prepared and
562 incubated as for (e) but supplemented with GSH (10 mM). (g) Increased frequency of SCVs

563 in the presence of GSH and by deletion of the transcription factor, Rex. Six cultures of *S.*
564 *aureus* USA300 JE2 or the corresponding *rex* mutant were grown in Tryptic Soy broth (TSB)
565 for 3 h at 37°C. Glutathione (GSH; 10 mM) was then added to three cultures and all cultures
566 were incubated for a further hour. Serial dilutions were plated on Tryptic Soy agar (TSA)
567 containing gentamicin or gentamicin and GSH and the plates were incubated at 37°C for 48
568 h. The concentration of gentamicin in the plates was 2 $\mu\text{g ml}^{-1}$ (G2) and the concentration of
569 GSH was 10 mM, but the *rex* mutant (open bars) exhibited enhanced resistance to
570 gentamicin when GSH was added to the plates and the concentration of gentamicin was
571 raised to 10 $\mu\text{g ml}^{-1}$ (G10). The chart shows the frequency of SCVs per 10^8 cells for cultures
572 unexposed (Broth: TSB; Plate: TSB + G2) and pre-exposed to GSH (Broth: TSB + GSH;
573 Plate: TSB + G2; or Broth: TSB + GSH; Plate: TSB + G2 or G10 + GSH). The error bars
574 show the standard deviation from the mean.

575

576 **Fig. 3.** Working model to account for the adaptation of *S. aureus* USA300 JE2 to low redox
577 potential environments. In the cytosol *S. aureus* encounters an aerobic low E_h environment
578 imposed by the presence of the reductant glutathione (GSH). Under these aerobic reducing
579 conditions bacterial aerobic respiration is impaired and electrons leak from the reduced
580 respiratory chain creating reactive oxygen species (ROS) that inhibit the activity of AgrA
581 (dashed lines) [40]. The potential DNA damage caused by ROS could be a source of
582 genotypic SCVs (dashed lines). Impaired electron transport leads to accumulation of
583 reduced electron carriers, including menaquinol (MQH₂) and NADH. Menaquinol (MQH₂)
584 activates the SrrBA two-component system and elevated NADH:NAD⁺ ratios inactivate Rex,
585 permitting expression of lactate dehydrogenase (Ldh1) by activation (\rightarrow) and derepression
586 (\perp), respectively, as well as up-regulation of terminal oxidase (*qox* and *cyd*) operons to
587 partially restore aerobic respiration (Fig. S5). Elevated NADH:NAD⁺ ratios also inhibit
588 pyruvate dehydrogenase complex (PDHC) activity, leading to reduction of pyruvate to
589 lactate, with concomitant oxidation of NADH, through the action of the newly synthesized

590 Ldh1 to ensure that redox balanced growth is achieved. This new mixed metabolic mode is
591 associated with a lower membrane electrical potential ($\Delta\Psi$), which impairs uptake of
592 aminoglycoside antibiotics and hence enhances resistance to gentamicin. These
593 transcriptional and physiological adaptations are consistent with the characteristics of
594 phenotypic small colony variants (SCVs).

Table 1. Transcripts that were altered in abundance by ≥ 10 -fold in response to perturbation of aerobic steady-state cultures of *S. aureus* USA300 JE2 by addition of dithiothreitol

Gene	Fold-change in transcript abundance at indicated time relative to the initial aerobic steady state							Redox regulator	Function
	2 min	5 min	10 min	15 min	30 min	60 min	1440 min		
Amino acids and derivatives									
SAUSA300_0008 (<i>hutH</i>)	12.75	13.09	8.33	5.71	4.49	5.22	3.09	AgrA, AirR	histidine ammonia-lyase
SAUSA300_0434 (<i>metB</i>)	0.13	0.12	0.11	0.13	0.16	0.12	0.09	CymR	cystathionine beta-lyase
SAUSA300_1227 (<i>thrC</i>)	13.45	9.07	3.46	1.63	0.68	1.37	2.57	Rot	threonine synthase
SAUSA300_1228 (<i>thrB</i>)	15.60	10.05	3.75	1.92	0.69	1.34	2.50	Rot	homoserine kinase
SAUSA300_1330 (<i>ilvA</i>)	1.19	1.31	1.81	1.67	2.57	5.02	28.84	AgrA, AirR	threonine ammonia-lyase
SAUSA300_1711 (<i>putA</i>)	9.23	7.79	5.69	6.04	7.37	7.84	13.37	SrrBA	proline dehydrogenase
SAUSA300_2277 (<i>hutI</i>)	21.33	21.40	9.49	5.11	3.81	8.22	5.86	AgrA	imidazolonepropionase
SAUSA300_2278 (<i>hutU</i>)	43.22	44.14	12.78	6.86	6.04	15.44	12.85	AgrA	uroconate hydratase
SAUSA300_2491 (<i>rocA</i>)	7.34	8.47	9.28	8.48	8.17	7.14	12.42	AgrA, AirR, MgrA, Rot	1-pyrroline-5-carboxylate dehydrogenase
Biosynthesis of cofactors, prosthetic groups, and carriers									
SAUSA300_0228 (<i>fadE</i>)	13.34	7.88	4.60	3.32	3.89	6.12	6.23	AirR, SarZ	acylCoA synthetase
Cell envelope									

SAUSA300_0315 (<i>nanA</i>)	9.93	12.74	9.75	10.42	10.70	12.55	32.68	MgrA	N-acetylneuraminate lyase
Anaerobic metabolism									
SAUSA300_0220 (<i>pflB</i>)	22.95	55.96	81.10	75.58	59.37	63.09	337.35	Rex, SarZ, SrrBA	pyruvate formate-lyase
SAUSA300_0221 (<i>pflA</i>)	11.44	31.64	54.22	52.71	37.10	37.80	189.68	Rex, SarZ, SrrBA	pyruvate formate-lyase 1-activating enzyme
SAUSA300_0235 (<i>ldh1</i>)	13.84	18.55	18.88	15.21	21.59	25.29	123.45	Rex, SrrBA	L-lactate dehydrogenase
SAUSA300_0536 (<i>hchA</i>)	0.23	0.18	0.10	0.09	0.08	0.08	0.08	AirR, CymR	D-lactate dehydratase/chaperone
SAUSA300_0594 (<i>adh</i>)	2.3	4.3	4.2	3.8	3.4	6.7	16.7	Rex SrrBA	alcohol dehydrogenase
SAUSA300_2343 (<i>narG</i>)	6.47	6.39	3.01	2.26	2.02	4.95	18.38	AirR, NreABC, Rex, Rot, SrrBA	nitrate reductase subunit
SAUSA300_2463 (<i>ddh</i>)	9.21	14.22	19.04	26.19	26.46	31.19	69.12	AgrA, AirR, MgrA, Rot	D-lactate dehydrogenase
Carbohydrates – central metabolism									
SAUSA300_1679 (<i>acsA</i>)	21.43	19.54	12.23	10.48	10.53	13.27	24.26	SarZ, SrrBA	acetylCoA synthase
SAUSA300_1331 (<i>ald</i>)	1.53	1.56	1.55	1.48	2.70	5.96	27.50	AgrA, AirR	alanine dehydrogenase
SAUSA300_1680 (<i>acuA</i>)	9.06	6.70	5.16	5.15	5.18	5.80	14.15	AirR	acetoin dehydrogenase
SAUSA300_1681	8.54	7.45	5.76	5.69	5.25	5.41	13.58	AirR	acetylCoA synthetase deacetylase
SAUSA300_1731 (<i>pckA</i>)	7.74	8.19	6.79	7.10	9.25	10.47	8.66	AgrA, AirR, SarZ	phosphoenolpyruvate carboxykinase
Regulatory functions									
SAUSA300_1989 (<i>agrB</i>)	0.23	0.19	0.16	0.14	0.12	0.11	0.08	AgrA, SarA	accessory gene regulator protein B
SAUSA300_1990	0.19	0.16	0.13	0.13	0.11	0.10	0.08	AgrA, SarA	accessory gene

(<i>agrD</i>)										regulator protein D
SAUSA300_1991	0.22	0.22	0.17	0.16	0.13	0.13	0.08	AgrA, SarA		accessory gene
(<i>agrC</i>)										regulator protein C
SAUSA300_1992	0.21	0.26	0.21	0.17	0.15	0.16	0.08	AgrA, SarA		accessory gene
(<i>agrA</i>)										regulator protein A
SAUSA300_2347	7.43	6.15	4.49	4.08	4.48	7.52	23.37	AirR, NreABC, Rex		nitrate reductase regulator
(<i>nirR</i>)										
Transport and binding proteins										
SAUSA300_0174	0.11	0.09	0.09	0.08	0.10	0.06	0.06	CymR, Rot, SarZ		ABC transporter, ATP- binding protein
(<i>ssuB</i>)										
SAUSA300_0333	10.50	10.65	7.04	5.71	2.87	3.03	4.96	AirR		PTS system, fructose subfamily, IIA component
SAUSA300_0448	6.11	12.08	10.77	9.11	5.60	5.65	6.63	AgrA, CymR, SarZ		PTS system, trehalose- specific IIBC component
(<i>treP</i>)										
SAUSA300_0887	14.09	4.82	1.48	1.15	1.13	2.37	2.44			oligopeptide ABC transporter, permease subunit
(<i>oppB</i>)										
SAUSA300_0888	14.64	4.87	1.62	1.22	1.11	2.14	2.46			oligopeptide ABC transporter, permease subunit
(<i>oppC</i>)										
SAUSA300_0889	14.01	6.77	2.22	1.43	0.99	2.19	2.18			oligopeptide import ATP-binding protein
(<i>oppD</i>)										
SAUSA300_0890	12.58	6.20	2.25	1.38	0.91	1.76	2.00			oligopeptide import ATP-binding protein
(<i>oppF</i>)										
SAUSA300_0891	11.72	9.97	3.58	1.76	1.10	2.47	1.70			oligopeptide ABC transporter, periplasmic binding protein
(<i>oppA</i>)										
SAUSA300_0914	12.24	5.26	1.84	1.39	1.23	1.96	1.97	MgrA		sodium:alanine symporter family protein
SAUSA300_1329	1.23	1.68	1.67	1.69	2.03	4.35	23.15	AgrA, AirR		amino acid permease
SAUSA300_2313	9.17	13.88	10.11	10.33	13.44	16.08	35.16	Rex		L-lactate permease

<i>(lctP2)</i>										
SAUSA300_2383	12.77	13.52	12.27	13.69	10.63	8.73	20.50			amino acid permease
SAUSA300_2449	8.36	11.03	6.57	4.60	4.82	5.10	5.39	AgrA		putative MFS transporter
Virulence factors										
SAUSA300_1067	0.04	0.04	0.02	0.02	0.01	0.01	0.00	AgrA, AirR, CymR		phenol soluble modulins β1
<i>(psmB1)</i>										
SAUSA300_1068	0.04	0.05	0.04	0.02	0.02	0.01	0.00	CymR		phenol soluble modulins β2
<i>(psmB2)</i>										
SAUSA300_1739	17.86	14.37	17.20	17.94	19.07	17.24	47.23	MgrA		putative immunoglobulin-blocking virulence protein
SAUSA300_1988	0.09	0.08	0.05	0.03	0.02	0.01	0.00	AgrA, AirR, SarA		RNA-III/delta-hemolysin
<i>(hld)</i>										
Hypothetical proteins and others										
SAUSA300_0108	2.04	3.45	3.46	3.13	2.79	4.70	10.22	AgrA, AirR, MgrA		carbon-oxygen lyase (myosin cross-reactive antigen)
SAUSA300_0173	0.19	0.19	0.15	0.13	0.11	0.11	0.07	CymR, Rot, SarZ		
SAUSA300_0227	26.45	23.40	12.99	12.14	5.89	10.16	9.83	AirR, SarZ		cyclohexanecarboxyl-CoA dehydrogenase
<i>(fadD)</i>										
SAUSA300_0228	13.34	7.88	4.60	3.32	3.89	6.12	6.23	AirR, SarZ		acylCoA synthetase
<i>(fadE)</i>										
SAUSA300_0229	10.78	9.51	5.16	3.81	3.22	3.79	5.35	AirR, SarZ		putative acylCoA transferase
<i>(fadX)</i>										
SAUSA300_0311	5.27	4.95	3.92	6.99	5.35	11.06	27.96			ribokinase
SAUSA300_0312	4.41	5.01	5.40	6.90	6.30	10.11	27.60			hypothetical protein
<i>(psuG)</i>										
SAUSA300_0862	8.27	10.39	10.75	9.97	9.26	9.98	35.01			glycerophosphoryl diester phosphodiesterase
<i>(glpQ)</i>										

SAUSA300_1224	5.14	7.06	5.83	5.64	6.93	8.16	13.88	AirR	hypothetical protein
SAUSA300_2132	10.70	19.23	21.67	13.73	13.65	14.09	13.77		hypothetical protein
SAUSA300_2164	0.27	0.26	0.18	0.15	0.12	0.10	0.08	AgrA, AirR, CymR, SarA	hypothetical protein
SAUSA300_2423	18.18	19.72	25.19	26.99	30.41	33.81	143.61	Rot	hypothetical protein

^aRedox responsive regulators are assigned on the basis of gene expression data [23-32].

Table 2. Glutathione increases retention of the SCV phenotype.

Patches with the indicated phenotype ^a					
Tryptic Soy agar					
		Unstable	Mixed	Stable	
Tryptic agar GSH	Soy plus	Unstable	20	1	0
		Mixed	6	35	7
		Stable	7	66	68

^aTwo hundred and ten *S. aureus* JE2 USA300 SCVs were picked from Tryptic Soy agar plates containing gentamicin (2 $\mu\text{g ml}^{-1}$). Each SCV was sequentially patched on to Tryptic Soy agar containing 10 mM GSH and Tryptic Soy agar alone. The plates were incubated for 3 days at 37°C and then the phenotypes were recorded: Unstable, reversion to normal phenotype; Mixed, patches were a mixture of normal and SCV phenotypes; Stable, SCV phenotype maintained. A representative pair of plates is shown in Fig. S4.





